#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

#### CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 7, 2024

		MARPAI, INC. (Exact name of Registrant as Specified in Its Charter)	)
(S	Delaware tate or Other Jurisdiction of Incorporation)	001-40904 (Commission File Number)	86-1916231 (IRS Employer Identification No.)
	615 Channelside Drive, Suite 20 Tampa, Florida	97	33602
	(Address of Principal Executive Of	fices)	(Zip Code)
	Registr	ant's Telephone Number, Including Area Code: 646 30	03-3483
	(Form	ner Name or Former Address, if Changed Since Last R	Report)
Check the appro	priate box below if the Form 8-K filing is in	ntended to simultaneously satisfy the filing obligation of	the registrant under any of the following provisions:
☐ Written cor	nmunications pursuant to Rule 425 under th	e Securities Act (17 CFR 230.425)	
☐ Soliciting n	naterial pursuant to Rule 14a-12 under the E	exchange Act (17 CFR 240.14a-12)	
☐ Pre-comme	ncement communications pursuant to Rule	14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))	
□ Pre-comme	ncement communications pursuant to Rule	13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))	
	Se	ecurities registered pursuant to Section 12(b) of the Ao	ct:
	Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Class A Com	mon Stock, par value \$0.0001 per share	MRAI	OTCQX Market
	k mark whether the registrant is an emerging change Act of 1934 (§ 240.12b-2 of this change Act of 1934)		ies Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
Emerging grow	h company ⊠		
	growth company, indicate by check mark if lards provided pursuant to Section 13(a) of		ion period for complying with any new or revised financial
Item 2.02 Resu	ts of Operations and Financial Condition	ı.	
		ease providing selected financial information for the thred by reference into this Item 2.02 in its entirety.	te and six months ended June 30, 2024. A copy of the press
Item 9.01 Finai	icial Statements and Exhibits.		
(d) Exhibits.			
Exhibit Number	Description		
99.1	Press release of Marpai, Inc. dated August	t 7, 2024	
104		ed as inline XBRL and contained in Exhibit 101)	

### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MARPAI, INC.

Date: August 7, 2024 By: /s/ Damien Lamendola

Name: Damien Lamendola Title: Chief Executive Officer



#### MARPAI REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS

Company continues to drive towards profitability

Tampa, August 7, 2024, Marpai, Inc. ("Marpai" or the "Company") (Nasdaq: MRAI), a technology platform company, which operates as a national Third-Party Administrator (TPA) through its subsidiaries and is transforming the \$22 billion TPA market by offering affordable, intelligent, healthcare solutions to self-funded employer health plans, announced financial results for the second quarter of 2024. The Company expects to hold a webcast to discuss the results on August 8, 2024.

#### Q2 2024 Financial Highlights:

- Net revenues were approximately \$7.2 million for the three months ended June 30, 2024, down \$2.9 million, or 28% lower year over year, compared to the three months ended June 30, 2023.
- Operating expenses were \$14.3 million for the three months ended June 30, 2024 (including a charge for the impairment of goodwill and intangibles of \$7.6 million), higher by \$3.4 million, or 32% higher year over year compared to the three months ended June 30, 2023.
- Operating loss was \$12.3 million for the three months ended June 30, 2024, higher by \$5.0 million, or 69% higher year over year compared to the three months ended June 30, 2023.
- Net loss was \$13.0 million for the three months ended June 30, 2024, higher by \$5.5 million, or 72% higher year over year compared to the three months ended June 30, 2023
- Basic and diluted earnings per share were (\$1.23) for the three months ended June 30, 2024, down (\$0.13) per share year over year compared to the three months ended June 30, 2023.

"The Company continues to show progress towards our goal of profitability," said Damien Lamendola, Chief Executive Officer of Marpai. "Additionally, our new sales team has been hitting the pavement and have set up a strong sales pipeline for Q1 2025 which we expect we will highlight after the third quarter."

John Powers, Marpai President commented, "The Marpai operations team has executed on our performance actions. Our customer service metrics and claim processing key process indicators (KPIs) have seen tremendous improvement year over year. Moreover, our clients and potential clients have recognized the impact of our Marpai Saves initiatives which drive down the overall cost of healthcare benefits."

#### Webcast and Conference Call Information

Marpai expects to host a conference call and webcast on Thursday, August 8, 2024, at 8:30 a.m. ET to review the Company's operational and financial highlights for its second quarter ended June 30, 2024.

Investors interested in listening to the conference call may do so by dialing (800)-836-8184 for domestic callers or +1-646-357-8785 for international callers, or via webcast: https://app.webinar.net/lrwPxYJnvpY



#### About Marpai, Inc.

Marpai, Inc. (OTCQX: MRAI) is a technology platform company which operates subsidiaries that provide TPA and value-oriented health plan services to employers that directly pay for employee health benefits. Primarily competing in the \$22 billion TPA sector serving self-funded employer health plans representing over \$1 trillion in annual claims. Through its *Marpai Saves* initiative, the Company works to deliver the healthiest member population for the health plan budget. Operating nationwide, Marpai offers access to leading provider networks including Aetna and Cigna and all TPA services. For more information, visit www.marpaihealth.com, the content of which is not incorporated by reference into this press release. Investors are invited to visit https://www.ir.marpaihealth.com. Investor Relations contact: Steve Johnson steve.johnson@marpaihealth.com

#### Forward-Looking Statement Disclaimer

This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties. Forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance," "may," "can," "could", "will", "potential", "should," "goal" and variations of these words or similar expressions. For example, the Company is using forward looking statements when it discusses the Q1 2025 sales pipeline and the expected timing of its highlighting of its pipeline. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect Marpai's current expectations and speak only as of the date of this release. Actual results may differ materially from Marpai's current expectations depending upon a number of factors. These factors include, among others, adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing the growth of the business. Except as required by law, Marpai does not undertake any responsibility to revise or update any forward-looking statements whether as a result of new information, future events or otherwise.

More detailed information about Marpai and the risk factors that may affect the realization of forward-looking statements is set forth in Marpai's filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov.



### MARPAI, INC. AND SUBSIDIARES CONDENSED CONSOLIDATED BALANCE SHEET

(in thousands, except share and per share data) (Unaudited)

	J	une 30, 2024		ember 31, 2023
ASSETS:				
Current assets:				
Cash and cash equivalents	\$	1,293	\$	1,147
Restricted cash		12,762		12,345
Accounts receivable, net of allowance for credit losses of \$0 and \$25		805		1,124
Unbilled receivable		568		768
Due from buyer for sale of business unit		800		800
Prepaid expenses and other current assets		967		901
Total current assets		17,195		17,085
Property and equipment, net		546		611
Capitalized software, net		933		2,127
Operating lease right-of-use assets		2,253		2,373
Goodwill		_		3,018
Intangible assets, net		_		5,177
Security deposits		1,267		1,267
Other long-term asset		22		22
Total assets	\$	22,216	\$	31,680
LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY				
Current liabilities:				
Accounts payable	\$	3,172	\$	4,649
Accrued expenses		2,643		2,816
Accrued fiduciary obligations		9,948		11,573
Deferred revenue		1,295		661
Current portion of operating lease liabilities		541		512
Current portion of convertible debenture, net		1,089		_
Other short-term liabilities		_		632
Total current liabilities		18,688		20,843
Other long-term liabilities		20,144		19,401
Convertible debenture, net of current portion		4,451		
Operating lease liabilities, net of current portion		3,405		3,684
Deferred tax liabilities		1,190		1,190
Total liabilities		47,878		45,118
COMMITMENTS AND CONTINGENCIES		17,070		15,110
STOCKHOLDERS' (DEFICIT) EQUITY				
Common stock, \$0.0001 par value, 227,791,050 shares authorized; 11,037,038 and 7,960,938 issued and outstanding at June 30, 2024 and December 31, 2023, respectively (1)		1		1
		68,455		63,307
Additional paid-in capital  Accumulated deficit		(94,118)		(76,746)
Total stockholders' (deficit) equity	_	(25,662)		(13,438)
Total liabilities and stockholders' (deficit) equity	\$	22,216	\$	31,680
(4)	Ψ	22,210	Ψ	31,000

MARPAI

### MARPAI, INC. AND SUBSIDIARES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except share and per share data) (Unaudited)

	Three Mor	nths Ended	
	June 30, 2024	June 30, 2023	
Revenue	\$ 7,189	\$ 10,047	
Costs and expenses			
Cost of revenue (exclusive of depreciation and amortization shown separately below)	5,174	6,430	
General and administrative	3,721	5,725	
Sales and marketing	436	1,473	
Information technology	1,210	1,319	
Research and development	8	523	
Depreciation and amortization	914	1,003	
Impairment of goodwill and intangible assets	7,588	_	
Loss on disposal of assets	_	344	
Facilities	411	500	

Total costs and expenses	19,462	17,317
Operating loss	(12,273)	(7,270)
Other income (expenses)		
Other income	120	50
Interest expense, net	(872)	(333)
Foreign exchange (loss) gain	(1)	(3)
Loss before provision for income taxes	(13,026)	(7,556)
Income tax expense		
Net loss	\$ (13,026)	\$ (7,556)
Net loss per share, basic & fully diluted	\$ (1.23)	\$ (1.10)
Weighted average common shares outstanding, basic and diluted	10,626,516	6,844,778

4

## MARPAI

### MARPAI, INC. AND SUBSIDIARES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except share and per share data) (Unaudited)

	Six Mont	hs Ended
	June 30, 2024	June 30, 2023
Revenue	\$ 14,574	\$ 19,719
Costs and expenses		
Cost of revenue (exclusive of depreciation and amortization shown separately below)	10,045	12,838
General and administrative	7,142	10,951
Sales and marketing	1,038	3,652
Information technology	2,334	3,506
Research and development	15	1,024
Depreciation and amortization	1,865	2,047
Impairment of goodwill and intangible assets	7,588	_
Loss on disposal of assets	_	344
Facilities	885	1,150
Total costs and expenses	30,912	35,512
Operating loss	(16,338)	(15,793)
Other income (expenses)		
Other income	240	101
Interest expense, net	(1,270)	(718)
Foreign exchange (loss) gain	(4)	(19)
Loss before provision for income taxes	(17,372)	(16,429)
Income tax expense	_	_
Net loss	\$ (17,372)	\$ (16,429)
Net loss per share, basic & fully diluted	\$ (1.73)	\$ (2.70)
Weighted average common shares outstanding, basic and diluted	10,016,146	6,080,200

5

# MARPAI

## MARPAI, INC. AND SUBSIDIARES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands, except share and per share data) (Unaudited)

	Three	<b>Three Months Ended</b>		
	June 30, 2024		June 30, 2023	
Cash flows from operating activities:				
Net loss	\$ (17,	372) \$	(16,429)	
Adjustments to reconcile net loss to net cash used in operating activities:  Depreciation and amortization	1	865	2.046	
Loss on disposal of assets	,	_	2,046 344	
Loss on sale of receivables Share-based compensation		306 421	990	
Shares issued to vendors in exchange for services		_	79	
Amortization of right-of-use asset		120	1,049	

Cash of termination of tease			22
Non-cash interest         646         776           Amontization of debt discount         62         —           Changes in operating assets and liabilities:         —         1           Accounts recivable and unbilled receivable         519         74           Prepaid expense and other assets         —         (425)           Security deposit         —         (147)         225           Security deposit         (1,625)         1,713         (235)           Accrued expenses         (1,625)         1,713         (235)           Accrued fibricary obligations         (1,625)         1,713         (205)         (1,713)           Operating lease liabilities         —         (40         (40)         (40	Gain on termination of lease	7.500	33
Clanges in operating assets and liabilities:   Clanges in operating assets and liabilities:   Accounts receivable and unbilled receivable   519   74     Prepaid expense and other assets   666   425     Prepaid expense and other assets   616   425     Accounts payable   (1,477   729     Accounts expenses   (1,427   729     Accounted expenses   (1,137   2625     Accounted expenses   (1,137   2625     Accounted expenses   (1,137   2625     Accounted payable   (1,252   1,713     Operating lease liabilities   (2,50   1,343     Due To related party   (2,50   1,343     Due To related party   (3,50   1,343     Due To related party   (3,50   1,343     Due To related party   (4,50   1,343     Other liabilities   (7,50   1,343     Disposal of property and equipment   (8,50   1,343     Ret each provided by (used in) investing activities   (8,50   1,343     Expenses   (8,50   1,343     Proceeds from issuance of common stock in a public offering, net   (8,13   1,343     Proceeds from issuance of common stock in a public offering, net   (8,13   1,343     Proceeds from issuance of common stock in a public offering, net   (8,13   1,343     Proceeds from issuance of common stock in a public offering, net   (8,13   1,343     Proceeds from issuance of common stock in a public offering, net   (8,13   1,343     Proceeds from issuance of common stock in a public offering, net   (8,13   1,343     Proceeds from issuance of common stock in a public offering, net   (8,13   1,343     Proceeds from issuance of common stock in a public offering, net   (8,13   1,343     Proceeds from issuance of common stock in a public offering, net   (8,13   1,343     Proceeds from issuance of common stock in a public offering, net   (8,13   1,343     Proceeds from issuance of common stock in a public offering, net   (8,13   1,343     Proceeds from issuance of common stock in a public offering, net   (8,13   1,343     Proceeds from issuance of common stock in a public offering, net   (8,13   1,343     Proceeds from issuance of common stock in a public of		. ,	776
Changes in operating assets and liabilities:   Accounts receivable and unbilled receivable   16			770
Accounts receivable and unbilled receivable         519         74           Prepaid expense and other assets         (66)         425           Security deposit         (1,477)         729           Accrued expenses         (1,173)         (235)           Accrued fiduciary obligations         (1,625)         1,713           Operating lease liabilities         (250)         (1,813)           Due To related parry         - (26)         (1,812)           Other liabilities         (731)         1,028           Net cash used in operating activities         - (818)           Net cash sued in operating activities         - (818)           Net cash row from investing activities         - (832)           Cash flows from investing activities         - (832)           Proceeds from issuance of common stock in a public offering, net         - (832)           Proceeds from issuance of common stock in a public offering, net         - (832)           Payments of convertible debentures         - (832)           Payments of convertible debenture issuance cost         - (832)           Payments of convertible debenture issuance cost         - (832)           Payments of convertible debenture issuance cost         - (832)           Proceeds from issuance of common stock in a private offering, net         - (2		02	_
Prepaid expense and other assets         (66)         425           Security deposit         —         (14)           Accounts payable         (1,477)         729           Accrued fiduciary obligations         (1,625)         1,713           Operating lease liabilities         (25)         (1,343)           Due To related parry         (27)         (28)           Other liabilities         (5,705)         (8,739)           Net cash incorparity activities         5,707         18           Net cash provided by (used in) investing activities         —         18           Vest cash provided by (used in) investing activities         —         6,432           Proceeds from fissance of common stock in a public offering, net         —         6,432           Proceeds from stock options exercises         1,509         —           Proceeds from issuance convertible debenture         5,978         —           Payments of convertible debenture issuance costs         (49)         —           Payments of common stock in a pub		510	7.4
Case			
Accounts payable         (1477)         729           Accrued feduciary obligations         (1625)         1,133           Operating lease liabilities         (25)         1,133           Due To related party         (26)         (1,343)           Due To related party         (37)         1,028           Net ash loor in lorparting activities         (373)         1,028           Net shows from investing activities         ————————————————————————————————————		(66)	
Accrued dexpenses         (1,73)         (235)           Accrued Induciary obligations         (1,625)         1,713           Operating lease liabilities         (250)         (1,343)           Due To related parry         (573)         (2,50)         (3,730)           Other liabilities         731         1,028           Net cash used in operating activities         6,705         8,730           Cash flows from investing activities         -         18           Net cash provided by (used in) investing activities         -         18           Cash flows from investing activities         -         18           Cash flows from financing activities         -         18           Cash flows from insuance of common stock in a public offering, net         -         6,432           Proceeds from issuance of common stock in a public offering, net         5,978         -           Payments of convertible debenture issuance costs         (499)         -           Payments to buyer of receivables         5,978         -           Payments to buyer of receivables of common stock in a public offering, net         6,32         -           Proceeds from issuance of common stock in a private offering, net         1,349         2,23,117           Net acsh provided by financing activities <t< td=""><td></td><td>(1.477)</td><td>( )</td></t<>		(1.477)	( )
Accrued fiduciary obligations   (1,025   1,715   1,7			
Operating lease liabilities         (3.44)           Due To related party         — (4.4)           Other liabilities         731         1,028           Net cash used in operating activities         (6.705)         (8.739)           Cash flow from investing activities:         — 18           Disposal of property and equipment         — 6.432         18           Net cash provided by (used in) investing activities         — 6.432         18           Proceeds from financing activities:         — 6.432         6.432           Proceeds from stouch convertible debentures         1,509         — 6.432           Proceeds from issuance of common stock in a public offering, net         5,978         — 6.432           Payments to convertible debenture issuance costs         (409)         — 6.432           Payments to buyer of receivables         (1,816)         — 6.432           Proceeds from issuance of common stock in a public offering, net         (631)         — 6.432           Proceeds from issuance of common stock in a public offering, net         (53)         (2,289)           Net cash provided by financing activities         5,32         (2,289)           Net cash requivalents and restricted cash         5,3         (2,289)           Cash, cash equivalents and restricted cash reported in the condensed consolidated balance sh		( /	( /
Due To related party         — (4)           Other liabilities         731         1,028           Net cash used in operating activities         6,739         8,739           Cash flows from investing activities         — 18           Disposal of property and equipment         — 18           Net cash provided by (used in junesting activities         — 18           Cash flows from financing activities         — 6,432           Proceeds from issuance of common stock in a public offering, net         — 5,978         — 6,432           Proceeds from issuance of convertible debentures         5,978         — 6           Proceeds from issuance of convertible debenture issuance costs         (499)         — 6           Payments to buyer of receivables         (1,816)         — 6           Payments to buyer of receivables         (499)         — 6           Proceeds from issuance of common stock in a public offering, net         (5,978         — 6           Proceeds from issuance of common stock in a public offering, net         (5,018)         — 7           Net ash provided by financing activities         2,277         — 7           Net ash provided by financing activities         563         2,289           Cash, cash equivalents and restricted cash at beginning of period		( / /	/
Other liabilities         731         1,028           Net cash used in operating activities:         6,709         8,739           Cash flows from investing activities:         18           Disposal of property and equipment         9         18           Net cash provided by (used in) investing activities:         -         18           Cash flows from financing activities:         -         6,432           Cash flows from financing activities:         -         6,432           Proceeds from issuance of common stock in a public offering, net         -         6,432           Proceeds from issuance convertible debentures         5,978         -           Payments of convertible debenture issuance costs         (499)         -           Payments of convertible debenture issuance costs         (499)         -           Payments of proceeds from issuance of common stock in a public offering, net         (518)         -           Proceeds from issuance of common stock in a private offering, net         2,727         -           Proceeds from issuance of common stock in a private offering, net         2,727         -           Net ash provided by financing activities         563         (2,289)           Cash, cash equivalents and restricted cash         563         (2,289)           Cash, cash equivalents and r		(230)	
Net cash used in operating activities         (8,739)           Cash flows from investing activities:         18           Disposal of property and equipment         —         18           Net cash provided by (used in) investing activities         —         18           Cash flows from financing activities:         —         6,432           Proceeds from issuance of common stock in a public offering, net         —         6,432           Proceeds from issuance of convertible debentures         5,978         —           Payments of convertible debenture issuance costs         (499)         —           Payments to buyer of receivables         (1,816)         —           Proceeds from issuance of common stock in a public offering, net         (631)         —           Proceeds from issuance of common stock in a private offering, net         (5,978         —           Proceeds from issuance of common stock in a private offering, net         (5,312)         —           Proceeds from issuance of common stock in a private offering, net         5,272         —           Net cash provided by financing activities         5,378         6,432           Net ach cash equivalents and restricted cash         2,12,22         2,22,22           Cash, cash equivalents and restricted cash at beginning of period         13,492         23,117      <		731	
Cash flows from investing activities:           Disposal of property and equipment         —         18           Net cash provided by (used in) investing activities         —         18           Cash flows from financing activities:           Proceeds from issuance of common stock in a public offering, net         —         6,432           Proceeds from issuance of convertible debentures         5,978         —           Payments of convertible debenture issuance costs         (1,816)         —           Payments to buyer of receivables         (1,816)         —           Proceeds from issuance of common stock in a public offering, net         (631)         —           Proceeds from issuance of common stock in a public offering, net         (631)         —           Proceeds from issuance of common stock in a private offering, net         5,272         —           Net cash provided by financing activities         5,32         2,227         —           Net decrease in cash, cash equivalents and restricted cash         553         (2,289)           Cash, cash equivalents and restricted cash at end of period         13,492         23,117           Cash, cash equivalents and restricted cash at end of period         1,293         8,726           Restricted cash         1,2762         1,210			
Disposal of property and equipment         —         18           Net cash provided by (used in) investing activities         —         18           Cash flows from financing activities:         —         6,432           Proceeds from issuance of common stock in a public offering, net         —         6,432           Proceeds from issuance of convertible debentures         5,978         —           Payments of convertible debenture issuance costs         (499)         —           Payments to buyer of receivables         (1,816)         —           Proceeds from issuance of common stock in a public offering, net         (631)         —           Proceeds from issuance of common stock in a private offering, net         2,727         —           Net cash provided by financing activities         7,268         6,432           Net decrease in cash, cash equivalents and restricted cash         563         (2,289)           Cash, cash equivalents and restricted cash at beginning of period         13,492         23,117           Cash, cash equivalents and restricted cash at end of period         13,492         23,117           Cash and cash equivalents, and restricted cash reported in the condensed consolidated balance sheet         2,29         2,20,22           Reconciliation of cash, cash equivalents, and restricted cash shown in the condensed consolidated statement of cash flow informati	Net eash used in operating activities	(6,703)	(8,739)
Net cash provided by (used in) investing activities:         —         18           Cash flows from financing activities:         —         6,432           Proceeds from issuance of common stock in a public offering, net         —         6,432           Proceeds from issuance of convertible debentures         1,509         —           Payments of convertible debenture issuance costs         (499)         —           Payments to buyer of receivables         (1,816)         —           Proceeds from issuance of common stock in a public offering, net         (631)         —           Proceeds from issuance of common stock in a private offering, net         2,727         —           Net cash provided by financing activities         563         (2,289           Net decrease in cash, cash equivalents and restricted cash         563         (2,289           Cash, cash equivalents and restricted cash at beginning of period         13,492         23,117           Cash, cash equivalents and restricted cash at end of period         13,492         23,218           Reconciliation of cash, cash equivalents, and restricted cash reported in the condensed consolidated balance sheet         1,293         8,726           Cash and cash equivalents         1,2762         12,102         12,102         12,102         12,102         12,102         12,102         12,102			
Cash flows from financing activities:         — 6,432           Proceeds from issuance of common stock in a public offering, net         1,509         — 6,432           Proceeds from issuance of convertible debentures         5,978         — 6           Payments of convertible debenture issuance costs         (499)         — 6           Payments to buyer of receivables         (1,816)         — 7           Payments to buyer of receivables         (1,816)         — 7           Proceeds from issuance of common stock in a public offering, net         (631)         — 7           Proceeds from issuance of common stock in a private offering, net         2,727         — 7           Net cash provided by financing activities         563         (2,289)           Net decrease in cash, cash equivalents and restricted cash         563         (2,289)           Cash, cash equivalents and restricted cash at beginning of period         13,492         23,117           Cash, cash equivalents and restricted cash at end of period         \$ 14,055         \$ 20,828           Reconciliation of cash, cash equivalents, and restricted cash reported in the condensed consolidated balance sheet           Cash and cash equivalents         \$ 1,293         \$ 8,726           Restricted cash         \$ 1,205         \$ 20,828           Total cash, cash eq	1 1 1 1 1		18
Proceeds from issuance of common stock in a public offering, net         1,509         −           Proceeds from issuance of convertible debentures         1,509         −           Payments of convertible debenture issuance costs         (499)         −           Payments to buyer of receivables         (1,816)         −           Proceeds from issuance of common stock in a public offering, net         (631)         −           Proceeds from issuance of common stock in a private offering, net         2,727         −           Net cash provided by financing activities         7,268         6,432           Net decrease in cash, cash equivalents and restricted cash         563         (2,289)           Cash, cash equivalents and restricted cash at beginning of period         13,492         23,117           Cash, cash equivalents and restricted cash at end of period         13,492         20,828           Reconciliation of cash, cash equivalents, and restricted cash reported in the condensed consolidated balance sheet           Cash and cash equivalents         \$ 1,293         \$ 8,726           Restricted cash         \$ 12,102         \$ 12,102           Total cash, cash equivalents and restricted cash shown in the condensed consolidated statement of cash flow         \$ 14,055         \$ 20,828           Supplemental disclosure of cash flow information         \$ 1,259	Net cash provided by (used in) investing activities		18
Proceeds from issuance of common stock in a public offering, net         1,509         −           Proceeds from issuance of convertible debentures         1,509         −           Payments of convertible debenture issuance costs         (499)         −           Payments to buyer of receivables         (1,816)         −           Proceeds from issuance of common stock in a public offering, net         (631)         −           Proceeds from issuance of common stock in a private offering, net         2,727         −           Net cash provided by financing activities         7,268         6,432           Net decrease in cash, cash equivalents and restricted cash         563         (2,289)           Cash, cash equivalents and restricted cash at beginning of period         13,492         23,117           Cash, cash equivalents and restricted cash at end of period         13,492         20,828           Reconciliation of cash, cash equivalents, and restricted cash reported in the condensed consolidated balance sheet           Cash and cash equivalents         \$ 1,293         \$ 8,726           Restricted cash         \$ 12,102         \$ 12,102           Total cash, cash equivalents and restricted cash shown in the condensed consolidated statement of cash flow         \$ 14,055         \$ 20,828           Supplemental disclosure of cash flow information         \$ 1,259	Cash flows from financing activities:		
Proceeds from stock options exercises Proceeds from issuance of convertible debentures  Payments of convertible debenture issuance costs Payments to buyer of receivables Proceeds from issuance of common stock in a public offering, net Proceeds from issuance of common stock in a public offering, net Proceeds from issuance of common stock in a private offering, net Proceeds from issuance of common stock in a private offering, net Proceeds from issuance of common stock in a private offering, net Proceeds from issuance of common stock in a private offering, net Proceeds from issuance of common stock in a private offering, net Proceeds from issuance of common stock in a private offering, net Proceeds from issuance of common stock in a private offering, net Proceeds from issuance of common stock in a private offering, net Proceeds from issuance of common stock in a private offering, net Proceeds from issuance of common stock in a private offering, net Proceeds from issuance of common stock in a public offering, net Proceeds from issuance of common stock in a public offering, net Proceeds from issuance of common stock in a public offering, net Proceeds from issuance of common stock in a public offering, net Proceeds from issuance of common stock in a public offering, net Proceeds from issuance of common stock in a public offering, net Proceeds from issuance of common stock in a public offering, net Proceeds from issuance of common stock in a public offering, net Proceeds from issuance of common stock in a public offering, net Proceeds from issuance of common stock in a public offering, net Proceeds from issuance of common stock in a public offering, net Proceeds from issuance of common stock in a public offering, net Proceeds from issuance of common stock in a public offering, net Proceeds from issuance of common stock in a public offering, net Proceeds from issuance of common stock in a public offering, net Proceeds from issuance of common stock in a public offering, net Proceeds from issuance of common stock in a pu		_	6,432
Proceeds from issuance of convertible debentures         5,978         —           Payments of convertible debenture issuance costs         (499)         —           Payments to buyer of receivables         (1,816)         —           Proceeds from issuance of common stock in a public offering, net         (631)         —           Proceeds from issuance of common stock in a private offering, net         2,727         —           Net cash provided by financing activities         7,268         6,432           Net decrease in cash, cash equivalents and restricted cash         563         (2,289)           Cash, cash equivalents and restricted cash at beginning of period         13,492         23,117           Cash, cash equivalents and restricted cash at end of period         \$ 14,055         \$ 20,828           Reconciliation of cash, cash equivalents, and restricted cash reported in the condensed consolidated balance sheet           Cash and cash equivalents         \$ 1,293         \$ 8,726           Restricted cash         12,762         12,102           Total cash, cash equivalents and restricted cash shown in the condensed consolidated statement of cash flows         \$ 14,055         \$ 20,828           Supplemental disclosure of cash flow information           Cash paid for interest         \$ 1,259         —           Supplemental disclosur		1,509	_
Payments of convertible debenture issuance costs  Payments to buyer of receivables  (1,816) — Proceeds from issuance of common stock in a public offering, net Proceeds from issuance of common stock in a private offering, net Proceeds from issuance of common stock in a private offering, net Proceeds from issuance of common stock in a private offering, net Proceeds from issuance of common stock in a private offering, net Proceeds from issuance of common stock in a private offering, net Proceeds from issuance of common stock in a private offering, net Proceeds from issuance of common stock in a private offering, net Proceeds from issuance of common stock in a private offering, net Proceeds from issuance of common stock in a private offering, net Proceeds from issuance of common stock in a public offering, net Proceeds from issuance of common stock in a public offering, net Proceeds from issuance of cash, cash equivalents and restricted cash Proceeds from issuance of cash at end of private of cash at end of private of cash at end of private of cash reperted in the condensed consolidated balance sheet  Cash and cash equivalents, and restricted cash reported in the condensed consolidated balance sheet  Cash and cash equivalents and restricted cash shown in the condensed consolidated balance sheet  Cash and cash equivalents and restricted cash shown in the condensed consolidated statement of cash flows  \$ 1,293 \$ 8,726 \$ 12,102 \$ 12,10		,	
Payments to buyer of receivables Proceeds from issuance of common stock in a public offering, net Proceeds from issuance of common stock in a private offering, net Proceeds from issuance of common stock in a private offering, net Proceeds from issuance of common stock in a private offering, net Proceeds from issuance of common stock in a private offering, net Proceeds from issuance of common stock in a private offering, net Proceeds from issuance of common stock in a private offering, net Proceeds from issuance of common stock in a private offering, net Proceeds from issuance of common stock in a private offering, net Proceeds from issuance of common stock in a private offering, net Proceeds from issuance of common stock in a private offering, net Proceeds from issuance of common stock in a private offering, net Proceeds from issuance of common stock in a private offering, net Proceeds from issuance of common stock in a private offering, net Proceeds from issuance of common stock in a private offering, net Proceeds from issuance of common stock in a private offering, net Proceeds from issuance of common stock in a private offering, net Proceeds from issuance of cash equivalents and restricted cash at equivalents and restricted cash at equivalents and restricted cash reported in the condensed consolidated balance sheet Cash, cash equivalents and restricted cash reported in the condensed consolidated balance sheet Cash and cash equivalents and restricted cash reported in the condensed consolidated balance sheet Cash, cash equivalents and restricted cash reported in the condensed consolidated balance sheet Cash, cash equivalents and restricted cash reported in the condensed consolidated balance sheet Cash, cash equivalents and restricted cash at end of period  13,492 23,117  Cash, cash equivalents and restricted cash at end of period  13,492 23,117  Cash, cash equivalents and restricted cash at end of period  13,492 23,117  Cash, cash equivalents and restricted cash at end of period  13,492 23,117  Cash, cash equi		5,978	_
Proceeds from issuance of common stock in a public offering, net Proceeds from issuance of common stock in a private offering, net Proceeds from issuance of common stock in a private offering, net Proceeds from issuance of common stock in a private offering, net Proceeds from issuance of common stock in a private offering, net Proceeds from issuance of common stock in a private offering, net Proceeds from issuance of common stock in a private offering, net Proceeds from issuance of common stock in a private offering, net Proceeds from issuance of common stock in a private offering, net Proceeds from issuance of common stock in a private offering, net Proceeds from issuance of common stock in a private offering, net Proceeds from issuance of common stock in a private offering, net Proceeds from issuance of common stock in a private offering, net Proceeds from issuance of common stock in a private offering, net Proceeds from issuance of cash equivalents and restricted cash Proceeds from issuance of cash equivalents and restricted cash at equivalents and restricted cash at equivalents and restricted cash reported in the condensed consolidated balance sheet Proceeds from issuance of cash equivalents and restricted cash reported in the condensed consolidated balance sheet Proceeds from issuance of cash equivalents and restricted cash reported in the condensed consolidated balance sheet Proceeds from issuance of cash equivalents and restricted cash reported in the condensed consolidated balance sheet Proceeds from issuance of cash equivalents and restricted cash reported cash reported in the condensed consolidated balance sheet Proceeds from issuance of cash equivalents and restricted cash reported cash reported in the condensed consolidated balance sheet Proceeds from issuance of cash equivalents and restricted cash reported in the condensed consolidated balance sheet Proceeds from issuance of cash equivalents and restricted cash reported cash reported in the condensed consolidated balance sheet Proceeds from issuan	Payments of convertible debenture issuance costs	(499)	_
Proceeds from issuance of common stock in a private offering, net  Net cash provided by financing activities  7,268 6,432  Net decrease in cash, cash equivalents and restricted cash  Cash, cash equivalents and restricted cash at beginning of period  13,492 23,117 Cash, cash equivalents and restricted cash at end of period  Reconciliation of cash, cash equivalents, and restricted cash reported in the condensed consolidated balance sheet Cash and cash equivalents  Restricted cash  12,762 12,102 Total cash, cash equivalents and restricted cash shown in the condensed consolidated statement of cash flows  Supplemental disclosure of cash flow information Cash paid for interest  Supplemental disclosure of non-cash activity	Payments to buyer of receivables	(1,816)	_
Net cash provided by financing activities 7,268 6,432  Net decrease in cash, cash equivalents and restricted cash  Cash, cash equivalents and restricted cash at beginning of period 13,492 23,117  Cash, cash equivalents and restricted cash at end of period \$ 14,055 \$ 20,828  Reconciliation of cash, cash equivalents, and restricted cash reported in the condensed consolidated balance sheet  Cash and cash equivalents \$ 1,293 \$ 8,726  Restricted cash \$ 12,762 \$ 12,102  Total cash, cash equivalents and restricted cash shown in the condensed consolidated statement of cash flow  Cash paid for interest \$ 1,259 \$ —  Supplemental disclosure of non-cash activity		(631)	_
Net decrease in cash, cash equivalents and restricted cash at beginning of period  Cash, cash equivalents and restricted cash at end of period  Reconciliation of cash, cash equivalents, and restricted cash reported in the condensed consolidated balance sheet  Cash and cash equivalents  Reconciliation of cash, cash equivalents, and restricted cash reported in the condensed consolidated balance sheet  Cash and cash equivalents  Restricted cash  12,762  12,102  Total cash, cash equivalents and restricted cash shown in the condensed consolidated statement of cash flows  Supplemental disclosure of cash flow information  Cash paid for interest  Supplemental disclosure of non-cash activity	Proceeds from issuance of common stock in a private offering, net	2,727	
Cash, cash equivalents and restricted cash at beginning of period  Cash, cash equivalents and restricted cash at end of period  Reconciliation of cash, cash equivalents, and restricted cash reported in the condensed consolidated balance sheet  Cash and cash equivalents  Restricted cash  Sangular cash equivalents and restricted cash shown in the condensed consolidated statement of cash flows  Supplemental disclosure of cash flow information  Cash paid for interest  Sangular cash equivalents and restricted cash at end of period  13,492  23,117  20,828	Net cash provided by financing activities	7,268	6,432
Cash, cash equivalents and restricted cash at beginning of period  Cash, cash equivalents and restricted cash at end of period  Reconciliation of cash, cash equivalents, and restricted cash reported in the condensed consolidated balance sheet  Cash and cash equivalents  Restricted cash  Sangular cash equivalents and restricted cash shown in the condensed consolidated statement of cash flows  Supplemental disclosure of cash flow information  Cash paid for interest  Sangular cash equivalents and restricted cash at end of period  13,492  23,117  20,828			
Cash, cash equivalents and restricted cash at beginning of period  Cash, cash equivalents and restricted cash at end of period  Reconciliation of cash, cash equivalents, and restricted cash reported in the condensed consolidated balance sheet  Cash and cash equivalents  Restricted cash  Sangular cash equivalents and restricted cash shown in the condensed consolidated statement of cash flows  Supplemental disclosure of cash flow information  Cash paid for interest  Sangular cash equivalents and restricted cash at end of period  13,492  23,117  20,828	Net decrease in each cash equivalents and restricted each	563	(2.289)
Cash, cash equivalents and restricted cash at end of period  Reconciliation of cash, cash equivalents, and restricted cash reported in the condensed consolidated balance sheet  Cash and cash equivalents  Restricted cash  12,762  12,102  Total cash, cash equivalents and restricted cash shown in the condensed consolidated statement of cash flows  Supplemental disclosure of cash flow information  Cash paid for interest  Supplemental disclosure of non-cash activity	, to detrouse in this, case equivalents and restricted case	303	(2,20))
Cash, cash equivalents and restricted cash at end of period  Reconciliation of cash, cash equivalents, and restricted cash reported in the condensed consolidated balance sheet  Cash and cash equivalents  Restricted cash  12,762  12,102  Total cash, cash equivalents and restricted cash shown in the condensed consolidated statement of cash flows  Supplemental disclosure of cash flow information  Cash paid for interest  Supplemental disclosure of non-cash activity	Cash, cash equivalents and restricted cash at beginning of period	13 492	23 117
Reconciliation of cash, cash equivalents, and restricted cash reported in the condensed consolidated balance sheet  Cash and cash equivalents  Restricted cash  12,762  12,102  Total cash, cash equivalents and restricted cash shown in the condensed consolidated statement of cash flows  \$ 1,293 \$ 8,726  12,102  Total cash, cash equivalents and restricted cash shown in the condensed consolidated statement of cash flows  \$ 14,055 \$ 20,828  Supplemental disclosure of cash flow information  Cash paid for interest  \$ 1,259 \$ —  Supplemental disclosure of non-cash activity	, I		
Cash and cash equivalents Restricted cash  Total cash, cash equivalents and restricted cash shown in the condensed consolidated statement of cash flows  Supplemental disclosure of cash flow information  Cash paid for interest  Supplemental disclosure of non-cash activity	Cash, cash equivalents and restricted cash at the or period	\$ 14,033	\$ 20,828
Cash and cash equivalents Restricted cash  Total cash, cash equivalents and restricted cash shown in the condensed consolidated statement of cash flows  Supplemental disclosure of cash flow information  Cash paid for interest  Supplemental disclosure of non-cash activity			
Restricted cash  Total cash, cash equivalents and restricted cash shown in the condensed consolidated statement of cash flows  Supplemental disclosure of cash flow information  Cash paid for interest  Supplemental disclosure of non-cash activity			
Total cash, cash equivalents and restricted cash shown in the condensed consolidated statement of cash flows  Supplemental disclosure of cash flow information  Cash paid for interest  Supplemental disclosure of non-cash activity		\$ 1,293	\$ 8,726
Supplemental disclosure of cash flow information Cash paid for interest  Supplemental disclosure of non-cash activity	Restricted cash	12,762	12,102
Cash paid for interest \$ 1,259 \$ — Supplemental disclosure of non-cash activity	Total cash, cash equivalents and restricted cash shown in the condensed consolidated statement of cash flows	\$ 14,055	\$ 20,828
Cash paid for interest \$ 1,259 \$ — Supplemental disclosure of non-cash activity	Supplemental disclosure of cash flow information		
Supplemental disclosure of non-cash activity		s 1.250	¢
	•	φ 1,239	Ψ
	Supplemental disclosure of non-cash activity		
		\$ —	\$ 198